American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Jul 2013
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
High-dose levofloxacin (L) (1,000 mg) was as active as moxifloxacin (M) (400 mg) in an early bactericidal activity trial, suggesting these fluoroquinolones could be used interchangeably. Whether pyrazinamide (Z) contributes sterilizing activity beyond the first 2 months in fluoroquinolone-containing second-line regimens remains unknown. ⋯ In murine tuberculosis, M had superior efficacy compared with L despite lower serum drug exposures and may remain the fluoroquinolone of choice for second-line regimens. Z contributed substantial sterilizing activity beyond 2 months in fluoroquinolone-containing second-line regimens, largely compensating for L's weaker activity.
-
Am. J. Respir. Crit. Care Med. · Jul 2013
Editorial CommentEarly recognition and treatment of severe sepsis.
-
Am. J. Respir. Crit. Care Med. · Jul 2013
Letter Case ReportsSharing insights and H7N9 patient clinical data.